Novo Nordisk A/S
NONOF
$131.74
-$6.25-4.53%
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 2.89B | 3.70B | 3.17B | 3.28B | 2.84B |
| Total Depreciation and Amortization | 453.79M | 424.30M | 94.56M | 368.75M | 318.08M |
| Total Amortization of Deferred Charges | -- | -- | 30.75M | -- | -- |
| Total Other Non-Cash Items | 2.63B | -750.60M | -519.28M | 627.10M | 1.61B |
| Change in Net Operating Assets | 1.31B | -1.29B | -1.40B | 1.70B | -586.64M |
| Cash from Operations | 7.29B | 2.08B | 1.38B | 5.98B | 4.18B |
| Capital Expenditure | -1.51B | -1.23B | -1.36B | -851.12M | -858.84M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -96.39M | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1.38B | 1.81B | -766.57M | -1.08B | -497.80M |
| Cash from Investing | -2.99B | 576.02M | -2.12B | -1.93B | -1.36B |
| Total Debt Issued | 34.51B | -- | -- | -- | -- |
| Total Debt Repaid | -5.05B | -317.00M | -355.00M | -261.00M | -373.00M |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -7.45B | -2.84B | -9.76B | -6.14B | -8.82B |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | 0.00 | -4.16B | 0.00 | -1.96B | 0.00 |
| Other Financing Activities | -5.33B | 5.33B | -- | -- | -3.39B |
| Cash from Financing | 2.41B | -3.84B | -1.46B | -2.90B | -1.84B |
| Foreign Exchange rate Adjustments | 6.06M | 6.41M | -30.17M | 61.04M | -9.50M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 6.71B | -1.17B | -2.24B | 1.21B | 969.89M |
